Technology · Health & biomedicine / Diagnostics & medtech
Organoids & organ-on-chip
Microphysiological systems mimicking human organs in vitro to replace animal testing and accelerate personalized medicine.
1 · What it gives
Organoids and Organ-on-a-Chip (OoC) systems, collectively known as Microphysiological Systems (MPS), represent a cutting-edge interdisciplinary frontier in biomedical engineering. They aim to create in vitro models of human organs and tissues that highly accurately reproduce their three-dimensional structural organization, cellular composition, biochemical microenvironment, mechanical stimulation, and physiological functions. By 2026, MPS have been recognized as the main technological alternative to the use of laboratory animals in toxicology, preclinical drug trials, and personalized medicine, significantly reducing the standard 5 to 7 year preclinical timeline while improving human predictive validity by up to 80%.
The key directions of the industry are:
- Organoids: Three-dimensional multicellular clusters self-organizing in vitro from induced pluripotent stem cells (hiPSCs) to study disease pathogenesis.
- Organ-on-a-Chip (OoC): Microfluidic devices containing living cultured human cells in controlled microchannels that recreate dynamic fluid flow and mechanical stress.
- Multi-Organ Chips: Body-on-a-Chip systems combining multiple “organs” into a single circulatory circuit to analyze systemic drug metabolism and toxicity.
- Personalized Medicine: Screening patient-derived organoids to select optimal oncological or cystic fibrosis treatments directly tailored to the individual.
Sectoral value chain#
[Stem Cells & Biomaterials] ──> [Microfluidic Chip Design] ──> [Cell Seeding & Co-culture]
│
(PDMS, Lithography, ECM)
│
▼
[Preclinical Drug Testing] <─── [Sensor Integration & Perfusion] <─── [Barrier Maturation]
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Cell Sourcing | Isolation of primary cells and directed differentiation of hiPSCs | In: Patient biopsies, growth factors. Out: Standardized hiPSC lines. |
| Chip Fabrication | Designing microchannels, photolithography, and functionalizing porous membranes | In: Photoresists, PDMS, cyclic olefins. Out: Microfluidic OoC platforms. |
| Biomaterials | Developing synthetic and natural hydrogels for 3D cultivation | In: Biopolymers, collagen, Matrigel. Out: Hydrogel matrices. |
| Microfluidic Assembly | Coating channels with extracellular matrix proteins and seeding cells to form barriers | In: Chip, matrix proteins, cell suspension. Out: Functioning microphysiological system. |
| Actuation & Sensing | Integrating micropumps and Transepithelial Electrical Resistance (TEER) electrodes | In: Electronic components, perfusion systems. Out: Automated monitoring OoC station. |
| Application & Assay | Preclinical screening of small molecules, monoclonal antibodies, or cell therapies | In: Investigational drugs, test systems. Out: Pharmacokinetic and toxicity data. |
Cross-cutting technologies of the sector:
- Precision Photolithography and Micro-molding: Lithography of SU-8 and injection molding of biocompatible thermoplastics enabling micron-scale channel geometries.
- In-channel 3D Bioprinting: Direct printing with living cells inside closed microchannels to instantly form complex blood capillaries.
- TEER Sensor Integration: Real-time, non-invasive measurement of tissue barrier integrity using microelectrodes placed above and below the porous membrane.
2 · What it replaces 2 · matched by industry
| D2E4 | Crop disease forecasting models, spore traps, pheromone and smart pest traps and field diagnostics — spray when risk is real instead of calendar-based fungicide and insecticide programmes Replaces: Fixed-interval ("calendar") protective fungicide sprays and routine insecticide applications regardless of pest pressure | EAC |
| D2E– | On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, … | DIAG |
3 · How to implement 6 steps
- 1Chip FabricationIn an ISO 5 cleanroom, liquid PDMS polymer is mixed with a curing agent and poured onto a silicon SU-8 master template containing the micro-relief of the channels. The mold is degassed in a vacuum and cured at 65°C for 4 hours.
- 2Assembly & BondingThe PDMS blank and a glass slide are cleaned and placed in a plasma chamber. Treatment with oxygen plasma activates the surfaces, which are then precisely aligned under a microscope and pressed together for covalent chemical cross-linking.
- 3ECM FunctionalizationThe assembled chips are sterilized via UV irradiation. A syringe pump injects a solution of extracellular matrix proteins (Type I collagen, fibronectin, or Matrigel) into the channels, incubating at 37°C to create an optimal substrate.
- 4Human Cell SeedingA suspension of human cells, such as primary lung microvascular endothelial cells, is introduced into the lower channel. After adhesion, alveolar epithelial cells are seeded into the upper channel, and the chip is incubated for 24 hours to form initial monolayers.
- 5Barrier MaturationThe chip is connected to an automated perfusion system simulating blood flow. The upper channel is exposed to air (Air-Liquid Interface), and cyclical vacuum pressure simulates lung breathing movements. Co-cultivation lasts 5–7 days until TEER sensors confirm a dense physiological barrier.
- 6Drug Screening AssayTesting & analyticsThe investigational drug substance is introduced into the perfusion flow at various concentrations. Sensors continuously record barrier integrity dynamics, while hourly perfusate samples are automatically withdrawn for mass spectrometry analysis of drug metabolites and toxicity markers.Who can do this step matched automaticallyEsco Aster Singapore5,000 L industrial scale“Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”✓ GMP industrial scale“ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”Vaxxinova Norway Norwayindustrial scale“Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.”Turion Labs Singapore“Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”
4 · Who delivers
Matched suppliers (matched automatically)
| NARO | Uganda | Research / RTO | active |
| Advanced Enzyme Technologies (NSE) | India | Producer | active |
In the services and supply catalogue 2 · paid service
Laboratory & analytical instruments · Reagents & kits
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Emulate | 🇺🇸 USA | Emulate S1 Organizer | Standardized platform with mechanical stretch | operating |
| TissUse | 🇩🇪 Germany | HUMIMIC Chips | Built-in micropumps, 4-organ co-culture | operating |
| Mimetas | 🇳🇱 Netherlands | OrganoPlate | Tubeless high-throughput plate format | operating |
| CN Bio Innovations | 🇬🇧 UK | PhysioMimix | Precision micro-perfusion control | operating |
| Daxiang Biotech | 🇨🇳 China | Dx-Chips | Scalable biocompatible plastic chips | operating |
| Wyss Institute | 🇺🇸 USA | Organ-on-a-chip R&D | Foundational mechanobiology patents | operating |
5 · Rules & route to market
Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
The United States pioneered the commercialization of OoC devices, heavily supported by robust academic centers and a progressive regulatory framework.
FDA Modernization Act 2.0, Wyss Institute, Emulate leadership#
- FDA Modernization Act 2.0: A revolutionary 2022 law abolishing the mandatory requirement for animal testing of new drugs before human clinical trials, legitimizing MPS data.
- Wyss Institute (Harvard): The birthplace of the world’s first functional “Lung-on-a-Chip,” generating foundational patents for OoC mechanobiology.
- Commercial Leadership: Boston-based Emulate Inc. is the world’s key supplier of standard chips, perfusion installations, and software, holding official validation partnerships with the FDA for toxicology.
European Union
The European Union prioritizes OoC technologies under strict ethical constraints on animal testing, especially driven by the REACH directive and cosmetic bans.
EUROoCS, multi-organ chips (TissUse), high-throughput platforms (Mimetas)#
- Multi-Organ Innovators: German company TissUse developed the proprietary HUMIMIC technology, integrating built-in pneumatic micropumps for long-term (up to 28 days) 4-organ systemic co-culturing.
- High-throughput Systems: Netherlands-based Mimetas created the OrganoPlate, a tubeless microfluidic chip formatted as a standard 384-well plate, enabling automated robotic screening without external pumps.
- European Infrastructure: The ORCHID project and the European Organ-on-Chip Society (EUROoCS) coordinate standardization and regulatory alignment with the EMA.
China
China is rapidly expanding its presence in the OoC industry, focusing on scalable chip production and specialized applications for traditional medicine.
High-throughput screening, TCM screening, Daxiang Biotech#
- Traditional Chinese Medicine (TCM) Screening: A unique state priority where “gut-liver-target” chips decipher how complex herbal extracts are absorbed and metabolized to exert systemic effects.
- Commercial Suppliers: Daxiang Biotech develops industrial OoC platforms made of biocompatible plastics replacing PDMS to prevent the absorption of small hydrophobic drug molecules.
- Leading Academic Centers: Institutions like the Dalian Institute of Chemical Physics (DICP) innovate new multi-organ chips and alternative biocompatible materials.
6 · Money: tenders & grants
7 · Tech stack & innovations
The modern production of microphysiological MPS systems relies on precision engineering and advanced materials.
- Precision Micro-molding from PDMS:
- Polydimethylsiloxane (PDMS) provides high optical transparency, elasticity for mechanical stretching, and gas permeability.
- Injection molding on silicon SU-8 templates ensures channel detailing down to 1 micron.
- Plasma Covalent Bonding:
- Low-pressure oxygen plasma treatment of PDMS and glass surfaces generates reactive silanol groups.
- Instant covalent cross-linking withstands high pumping pressures without channel depressurization.
- Automated Microsensor Detection:
- Gold or platinum microelectrodes sputtered onto the glass substrate allow continuous reading of transepithelial resistance (TEER).
- Enables real-time monitoring of oxygen partial pressure and pH directly in the cell culture zone.
Sources 6 · 0 independent · 6 producer sites
Producers' own sites 6
- Emulate producer checked 2026-06-12 · link not kept
- Tissuse producer checked 2026-04-23 · link not kept
- Mimetas producer checked 2026-05-22 · link not kept
- Cn bio producer checked 2026-05-29 · link not kept
- Daxiang biotech producer checked 2026-06-25 · link not kept
- Wyss institute producer checked 2026-06-16 · link not kept